We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
medical-devices: Archive
Philips (PHG) Receives FDA Warning Letter Regarding CT Systems
by Zacks Equity Research
Philips (PHG) receives a warning letter from the FDA in respect of a manufacturing plant in China regarding faults in the manufacturing of CT systems.
ECLPositive Net Change PHGPositive Net Change BDXPositive Net Change IDXXPositive Net Change
medical medical-devices
Factors Setting the Tone For Lantheus' (LNTH) Q1 Earnings
by Zacks Equity Research
Lantheus' (LNTH) first-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
CAHNegative Net Change EWNegative Net Change LNTHPositive Net Change SIBNPositive Net Change
medical medical-devices
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
ECLPositive Net Change UHSPositive Net Change THCNegative Net Change BPMCPositive Net Change
earnings medical medical-devices
Integer Holdings (ITGR) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust Medical Sales, along with strength in all the product lines.
LHPositive Net Change ALGNNegative Net Change RMDPositive Net Change ITGRNegative Net Change
earnings medical medical-devices
3 Medical Products Stocks Set to Beat This Earnings Season
by Urmimala Biswas
Here are three stocks, TXG, CAH and HOLX, which are expected to beat earnings estimates in the ongoing reporting cycle.
BSXNegative Net Change LHPositive Net Change CAHNegative Net Change HOLXPositive Net Change TXGPositive Net Change
earnings medical medical-devices
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
EWNegative Net Change EXASPositive Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?
by Moumi Mondal
Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.
INSPPositive Net Change TMDXPositive Net Change HITINo Net Change LFWDPositive Net Change
earnings medical medical-devices
ResMed (RMD) Q3 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
ResMed's (RMD) fiscal 2024 third-quarter performance reflects another strong period of execution across the entire business, resulting in impressive top and bottom-line growth.
RMDPositive Net Change HCANegative Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Cencora's (COR) second-quarter fiscal 2024 results are likely to reflect solid performance in the U.S. Healthcare Solutions segment.
CAHNegative Net Change CORPositive Net Change NVCRPositive Net Change SIBNPositive Net Change
medical medical-devices
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
ECLPositive Net Change BDXPositive Net Change DXCMNegative Net Change IDXXPositive Net Change
earnings medical medical-devices
ICON (ICLR) Q1 Earnings Surpass Estimates, Margins Expand
by Zacks Equity Research
ICON's (ICLR) first-quarter 2024 performance is driven by its efficient service delivery and strong cost control.
ICUIPositive Net Change ICLRPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Align Technology (ALGN) Q1 Earnings Top, 2024 Sales View Up
by Zacks Equity Research
Align Technology's (ALGN) first quarter 2024 revenue growth was up across all regions and was driven by strong Clear Aligner volumes, primarily in the Asia Pacific region.
ALGNNegative Net Change ICUIPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change RVTYNegative Net Change
medical medical-devices
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
ECLPositive Net Change BDXPositive Net Change CNMDPositive Net Change IDXXPositive Net Change
earnings medical medical-devices
Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions
by Zacks Equity Research
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change VEEVPositive Net Change
medical medical-devices
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change WSTNegative Net Change
earnings medical medical-devices
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
LHPositive Net Change EXASPositive Net Change INSPPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
PODDPositive Net Change CHENegative Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
TMOPositive Net Change ICUIPositive Net Change EXASPositive Net Change INSPPositive Net Change
earnings medical medical-devices
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Growth across Microbial Solutions and Biologics Testing businesses is likely to have contributed to Charles River's (CRL) Q1 revenues, offset by lower sales volume in the small model business.
CRLPositive Net Change PODDPositive Net Change LNTHPositive Net Change TMDXPositive Net Change
earnings medical medical-devices
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
by Urmimala Biswas
SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
SYKNegative Net Change ZBHNegative Net Change
earnings medical medical-devices
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
by Zacks Equity Research
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
ECLPositive Net Change BDXPositive Net Change IDXXPositive Net Change PENNegative Net Change
medical medical-devices
Rising Demand Likely to Aid GE HealthCare's (GEHC) Q1 Earnings
by Zacks Equity Research
GE HealthCare's (GEHC) first-quarter results are expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.
CAHNegative Net Change EWNegative Net Change SIBNPositive Net Change GEHCPositive Net Change
medical medical-devices
Boeing Mixed in Q1, TMO Beats; Durable Goods In-Line
by Mark Vickery
Boeing posted a slimmer loss per share while Thermo Fisher outperformed. Durable Goods performed as expected.
BAPositive Net Change FNegative Net Change IBMNegative Net Change CMGPositive Net Change TMOPositive Net Change METAPositive Net Change
aerospace earnings medical-devices restaurants tech-stocks
Insulet (PODD) Awaits Q1 Earnings Release: Here's What to Expect
by Zacks Equity Research
Strong global new customer starts fueled by the ongoing Omnipod 5 demand are expected to significantly benefit Insulet's (PODD) first-quarter performance.
HCANegative Net Change SRPTPositive Net Change PODDPositive Net Change TMDXPositive Net Change
earnings medical medical-devices